Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib + Chemo in Uterine/Ovarian Carcinosarcoma
NCT03206177Phase 1Completed
- Sponsor
- University of Oklahoma
- Start
- Aug 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in uterine carcinosarcoma (UCS), ovarian carcinosarcoma (OCS) and fallopian tube carcinosarcoma, sponsored by University of Oklahoma. Primary endpoint: Proportion of Patients With Completion of 4 Cycles of CT + GB at 2 years. Started Aug 2017; status: completed.
02
Drugs
galunisertib
03
Conditions
uterine carcinosarcoma (UCS)ovarian carcinosarcoma (OCS)fallopian tube carcinosarcoma
Beyond the preview
Go deeper on NCT03206177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206177.